Compare Alphabet Inc Class A (GOOGL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs GSK plc — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: Alphabet Inc Class A is far larger — about 46.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and GSK plc for 93 Days on average.
| GOOGL | GSK | |
|---|---|---|
Market Cap | $4.24T | $91.88B |
Volume | 23,392,850 | 7,730,529 |
Sector | Media | Health |
52-Week High | $402.62 | $61.18 |
52-Week Low | $236.59 | $43.24 |
Typical Hold Time | 85 Days | 93 Days |
Enterprise Value | $4.13T | $111.88B |
Dividend Yield | 0.25% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $351.66, up 0.33% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 86.75% analyst buy rating support positive sentiment, while YouTube's subscription price increase and AI partnerships with Anthropic and Intel highlight growth initiatives.
GOOGL presents a compelling investment case with 72 buy ratings and a $431.83 consensus price target offering 23% upside. Strong cash flow generation ($164.7B operating cash flow in 2025) and AI leadership position the stock for continued growth, though antitrust scrutiny and market volatility remain key risks requiring monitoring.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
